Key result
Paroxysmal atrial fibrillation comprises 25% to 62% of all atrial fibrillation cases, but its management strategies remain limited by reliance on small randomized trials and inconsistent definitions.
Population
Patients with paroxysmal atrial fibrillation (PAF)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Management of paroxysmal AF should parallel sustained AF; leaves open need for large dedicated RCTs with consistent definitions.
Structured PICO
P
Population
Patients with paroxysmal atrial fibrillation (PAF)
I
Intervention
Pharmacological therapies (Class 1c drugs, beta-blockers, amiodarone, warfarin, aspirin) and non-pharmacological options (pacemakers, electrophysiological techniques, implantable atrial defibrillator)
O
Outcome
Prevention of paroxysms and long-term maintenance of sinus rhythm
The management of paroxysmal atrial fibrillation should generally parallel that of sustained AF, but current strategies are limited by a lack of large, dedicated randomized controlled trials.
Limitations
- Evidence from small randomized trials
- Inconsistencies over the definition of the arrhythmia
- Inclusion of only symptomatic subjects
- Evidence for antithrombotic therapy is based on epidemiological studies and subgroup analyses
- evidence from small randomized trials
- inconsistencies over the definition of the arrhythmia
- inclusion of only symptomatic subjects
- evidence for antithrombotic therapy is based on epidemiological studies and subgroup analyses
Cite This Study
Gregory Y.H. Lip (2001) conducted a review in Paroxysmal atrial fibrillation. Management strategies was evaluated. Paroxysmal atrial fibrillation comprises 25% to 62% of all atrial fibrillation cases, but its management strategies remain limited by reliance on small randomized trials and inconsistent definitions.